These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 24623375

  • 1. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
    Kazankov K, Barrera F, Møller HJ, Bibby BM, Vilstrup H, George J, Grønbaek H.
    Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
    [Abstract] [Full Text] [Related]

  • 2. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
    Lidofsky A, Holmes JA, Feeney ER, Kruger AJ, Salloum S, Zheng H, Seguin IS, Altinbas A, Masia R, Corey KE, Gustafson JL, Schaefer EA, Hunt PW, Deeks S, Somsouk M, Chew KW, Chung RT, Alatrakchi N.
    J Infect Dis; 2018 Sep 22; 218(9):1394-1403. PubMed ID: 29868909
    [Abstract] [Full Text] [Related]

  • 3. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
    Dultz G, Gerber L, Farnik H, Berger A, Vermehren J, Pleli T, Zeuzem S, Piiper A, Kronenberger B, Waidmann O.
    J Viral Hepat; 2015 Apr 22; 22(4):427-32. PubMed ID: 25181653
    [Abstract] [Full Text] [Related]

  • 4. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
    Laursen TL, Wong GL, Kazankov K, Sandahl T, Møller HJ, Hamilton-Dutoit S, George J, Chan HL, Grønbaek H.
    J Gastroenterol Hepatol; 2018 Feb 22; 33(2):484-491. PubMed ID: 28618015
    [Abstract] [Full Text] [Related]

  • 5. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
    Lund Laursen T, Brøckner Siggard C, Kazankov K, Damgaard Sandahl T, Møller HJ, Ong A, Douglas MW, George J, Tarp B, Hagelskjaer Kristensen L, Lund Laursen A, Hiramatsu A, Nakahara T, Chayama K, Grønbaek H.
    Scand J Gastroenterol; 2018 Aug 22; 53(8):986-993. PubMed ID: 29987961
    [Abstract] [Full Text] [Related]

  • 6. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
    Kazankov K, Barrera F, Møller HJ, Rosso C, Bugianesi E, David E, Younes R, Esmaili S, Eslam M, McLeod D, Bibby BM, Vilstrup H, George J, Grønbaek H.
    Liver Int; 2016 Oct 22; 36(10):1549-57. PubMed ID: 27102725
    [Abstract] [Full Text] [Related]

  • 7. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
    Kazankov K, Tordjman J, Møller HJ, Vilstrup H, Poitou C, Bedossa P, Bouillot JL, Clement K, Grønbaek H.
    J Gastroenterol Hepatol; 2015 Aug 22; 30(8):1293-300. PubMed ID: 25772748
    [Abstract] [Full Text] [Related]

  • 8. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A, Støy S, Thomsen KL, Hvas CL, Agnholt J, Dahlerup JF, Møller HJ, Grønbaek H.
    Scand J Immunol; 2014 Dec 22; 80(6):417-23. PubMed ID: 25346048
    [Abstract] [Full Text] [Related]

  • 9. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis.
    Baeten D, Møller HJ, Delanghe J, Veys EM, Moestrup SK, De Keyser F.
    Arthritis Rheum; 2004 May 22; 50(5):1611-23. PubMed ID: 15146432
    [Abstract] [Full Text] [Related]

  • 10. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.
    Andersen ES, Rødgaard-Hansen S, Moessner B, Christensen PB, Møller HJ, Weis N.
    Eur J Clin Microbiol Infect Dis; 2014 Jan 22; 33(1):117-22. PubMed ID: 24424890
    [Abstract] [Full Text] [Related]

  • 11. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure.
    Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M.
    J Gastroenterol; 2005 Jan 22; 40(1):52-6. PubMed ID: 15692789
    [Abstract] [Full Text] [Related]

  • 12. The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients.
    Dultz G, Gerber L, Zeuzem S, Sarrazin C, Waidmann O.
    J Viral Hepat; 2016 Apr 22; 23(4):267-73. PubMed ID: 26554542
    [Abstract] [Full Text] [Related]

  • 13. Soluble CD163 and interleukin-6 are increased in aqueous humour from patients with endothelial rejection of corneal grafts.
    Funding M, Vorum H, Nexø E, Moestrup SK, Ehlers N, Møller HJ.
    Acta Ophthalmol Scand; 2005 Apr 22; 83(2):234-9. PubMed ID: 15799739
    [Abstract] [Full Text] [Related]

  • 14. Soluble CD163 is associated with noninvasive measures of liver fibrosis in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected women.
    Kuniholm MH, Hanna DB, Landay AL, Kaplan RC, Ley K.
    Hepatology; 2015 Feb 22; 61(2):734-5. PubMed ID: 25044447
    [No Abstract] [Full Text] [Related]

  • 15. CD14+ monocytes and CD163+ macrophages correlate with the severity of liver fibrosis in patients with chronic hepatitis C.
    Zhao SX, Li WC, Fu N, Kong LB, Zhang QS, Han F, Ren WG, Cui P, Du JH, Wang BY, Zhang YG, Wang RQ, Kong L, Nan YM.
    Exp Ther Med; 2020 Dec 22; 20(6):228. PubMed ID: 33149783
    [Abstract] [Full Text] [Related]

  • 16. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
    Grønbaek H, Sandahl TD, Mortensen C, Vilstrup H, Møller HJ, Møller S.
    Aliment Pharmacol Ther; 2012 Jul 22; 36(2):173-80. PubMed ID: 22591184
    [Abstract] [Full Text] [Related]

  • 17. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
    Axelsson J, Møller HJ, Witasp A, Qureshi AR, Carrero JJ, Heimbürger O, Bárány P, Alvestrand A, Lindholm B, Moestrup SK, Stenvinkel P.
    Am J Kidney Dis; 2006 Dec 22; 48(6):916-25. PubMed ID: 17162146
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
    Waidmann O, Köberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiß M, Kronenberger B, Piiper A.
    J Hepatol; 2013 Oct 22; 59(4):769-79. PubMed ID: 23792028
    [Abstract] [Full Text] [Related]

  • 19. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
    Sugaya M, Miyagaki T, Ohmatsu H, Suga H, Kai H, Kamata M, Fujita H, Asano Y, Tada Y, Kadono T, Okochi H, Sato S.
    J Dermatol Sci; 2012 Oct 22; 68(1):45-51. PubMed ID: 22884782
    [Abstract] [Full Text] [Related]

  • 20. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease.
    Rødgaard-Hansen S, St George A, Kazankov K, Bauman A, George J, Grønbæk H, Jon Møller H.
    Scand J Clin Lab Invest; 2017 Nov 22; 77(7):498-504. PubMed ID: 28715286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.